Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Exome Asset Management LLC

Exome Asset Management LLC boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 114.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 100,367 shares of the company’s stock after acquiring an additional 53,467 shares during the quarter. Apellis Pharmaceuticals accounts for 1.9% of Exome Asset Management LLC’s portfolio, making the stock its 22nd largest position. Exome Asset Management LLC owned about 0.08% of Apellis Pharmaceuticals worth $2,895,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Wolverine Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. True Wealth Design LLC bought a new stake in Apellis Pharmaceuticals in the third quarter worth about $27,000. Capital Performance Advisors LLP acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at about $56,000. KBC Group NV grew its stake in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares during the last quarter. Finally, nVerses Capital LLC grew its stake in shares of Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after purchasing an additional 2,100 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS opened at $33.19 on Friday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $73.80. The company has a fifty day moving average price of $29.65 and a 200 day moving average price of $34.81. The stock has a market cap of $4.13 billion, a P/E ratio of -16.35 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the prior year, the company posted ($1.17) earnings per share. The company’s revenue for the quarter was up 78.3% on a year-over-year basis. Analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Insider Activity

In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. This trade represents a 27.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

APLS has been the subject of a number of research reports. Morgan Stanley initiated coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price for the company. The Goldman Sachs Group reduced their price objective on Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Mizuho cut their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. Needham & Company LLC decreased their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, HC Wainwright cut their price objective on Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $49.94.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).